Comparing the Efficacy of Kligman Formula Alone and with Fractional Q Switched Nd: YAG Laser in Treatment of Melasma

Document Type : Original Article (s)

Authors

1 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine, Islamic Azad University, Najafabad Branch, Najafabad, Iran

4 General Practitioner, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Melasma is an acquired pigmentation disorder in all types of skin especially in women. Researchers are certain to find effective and less recurrence rate treatment. This study compared the effectiveness of Kligman formula alone and its combination therapy with fractional Q switched Nd: YAG laser in the treatment of melasma.Methods: In this clinical trial, 50 patients with melasma were randomly divided into two groups of 25. The first group treated with Kligman formula and the second group treated with combination of Kligman formula and fractional Q switched Nd: YAG laser. Area expansion, pigmentation and melasma uniformity, melasma area and severity index score (MASI) score, patient opinion immediately after the completion of treatment and 6 months after starting it, were recorded. The results were analyzed using ANOVA test.Findings: In both methods, there were significant differences after treatment in the development of pigmentation and MASI score compared to before it; but no significant differences were observed between the two methods. The inverse relation was observed between the age and the result of treatment and recurrence of melasma in both groups. Dry skin was occurred in one case of combination therapy.Conclusion: In this study, significant improvement was seen in both groups; but, there was no significant difference between the two approaches. It seems that increasing the number and reducing the time between laser sessions can create a more appropriate response. In addition, due to the recurrence of melasma after the end of treatment, there is a need for continuation the treatment using lightening compounds as Kligman formula and Peel felt.

Keywords

References

  1. Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg 2012; 5(2): 93-103.
  2. Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med 2008; 40(2): 134-8.
  3. Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol 2009; 48(1): 22-6.
  4. Bansal C, Naik H, Kar HK, Chauhan A. A Comparison of Low-Fluence 1064-nm Q-Switched Nd: YAG Laser with Topical 20% Azelaic Acid Cream and their Combination in Melasma in Indian Patients. J Cutan Aesthet Surg 2012; 5(4): 266-72.
  5. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat 2007; 18(1): 5-9.
  6. Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol 2014; 53(4): 440-4.
  7. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011; 65(4): 699-714.
  8. Kroon MW, Wind BS, Beek JF, van der Veen JP, Nieuweboer-Krobotova L, Bos JD, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol 2011; 64(3): 516-23.
  9. Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. J Drugs Dermatol 2011; 10(12): 1439-42.
  10. Iraji F, Tagmirriahi N, Gavidnia K. Comparison between the efficacy of 10% zinc sulfate solution with 4% hydroquinone cream on improvement of melasma. Adv Biomed Res 2012; 1: 39.
  11. Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci 2014; 19(8): 753-7.
  12. Majid I. Mometasone-based triple combination therapy in melasma: is it really safe? Indian J Dermatol 2010; 55(4): 359-62.
  13. Stratigos AJ, Dover JS, Arndt KA. Laser treatment of pigmented lesions--2000: how far have we gone? Arch Dermatol 2000; 136(7): 915-21.
  14. Goldstein BG, Goldstein AO, Callender VD. Melasma. 2014; Uptodate [Online]. [cited 2014 Jan 23]; Available from: URL:
  15. http://www.uptodate.com/contents/melasma
  16. Ferreira CT, Hassun K, Sittart A, de L, V. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol 2007; 6(1): 36-9.
  17. Lee DB, Suh HS, Choi YS. A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients. J Dermatolog Treat 2014; 25(6): 523-8.
  18. Hexsel D, Soirefmann M, Fernandes JD, Siega C. Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination. J Drugs Dermatol 2014; 13(4): 444-8.
  19. Suh KS, Sung JY, Roh HJ, Jeon YS, Kim YC, Kim ST. Efficacy of the 1064-nm Q-switched Nd: YAG laser in melasma. J Dermatolog Treat 2011; 22(4): 233-8.
  20. Park KY, Kim DH, Kim HK, Li K, Seo SJ, Hong CK. A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma. Clin Exp Dermatol 2011; 36(8): 864-70.
  21. Zhou X, Gold MH, Lu Z, Li Y. Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma. Dermatol Surg 2011; 37(7): 962-70.
  22. Na SY, Cho S, Lee JH. Intense Pulsed Light and Low-Fluence Q-Switched Nd: YAG Laser Treatment in Melasma Patients. Ann Dermatol 2012; 24(3): 267-73.
  23. Wang HW, Liu KY. Efficacy and safety of low-energy QS Nd:YAG and QS alexandrite laser for melasma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009; 31(1): 45-7. [In Chinese].
  24. Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd: YAG laser with low pulse energy. Clin Exp Dermatol 2009; 34(8): e847-e850.
  25. Karn D, K C S, Amatya A, Razouria EA, Timalsina M, Suwal A. Q-Switched Neodymium-Doped Yttrium Aluminum Garnet laser therapy for pigmented skin lesions: efficacy and safety. Kathmandu Univ Med J (KUMJ ) 2012; 10(38): 46-50.
  26. Sim JH, Park YL, Lee JS, Lee SY, Choi WB, Kim HJ, et al. Treatment of melasma by low-fluence 1064 nm Q-switched Nd:YAG laser. J Dermatolog Treat 2014; 25(3): 212-7.
  27. Kar HK, Gupta L, Chauhan A. A comparative study on efficacy of high and low fluence Q-switched Nd:YAG laser and glycolic acid peel in melasma. Indian J Dermatol Venereol Leprol 2012; 78(2): 165-71.
  28. Kauvar AN. The evolution of melasma therapy: targeting melanosomes using low-fluence Q-switched neodymium-doped yttrium aluminium garnet lasers. Semin Cutan Med Surg 2012; 31(2): 126-32.
  29. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72(1): 67-72.
  30. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111(1): 40-8.
  31. Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. J Dermatolog Treat 2010; 21(5): 276-81.
Journal of Isfahan Medical School
Volume 33, Issue 342 - Serial Number 342
May and June 2015
Pages 1095-1106

Files

History

  • Receive Date: 11 July 2015
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics